FAQ

Our stock is traded on the NASDAQ under the symbol MNMD.

We were incorporated in 2010 in British Columbia.

We went public in February 2020 through a reverse takeover transaction and then uplisted to Nasdaq in April 2021.

Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States

December 31st

Computershare Investor Services
100 University Ave.
8th Floor, North Tower
Toronto, Ontario M5J2Y1
Canada
T: 1-800-564-6253 (toll free in Canada and US)
T: 514-982-7555 (international direct dial)
F: 1-888-453-0330

KPMG LLP

You can view all SEC filings here.

You can view our Transfer Agent contact information here or further up on this FAQ page.

MindMed does not pay a dividend on stock, and does not foresee doing so in the immediate future. Accordingly, MindMed does not offer a DRIP (Dividend Reinvestment Program).

Currently, shares are not available for purchase directly from MindMed and we do not have a direct purchase program available.

If your shares are held in your name, you may contact Computer Investor Services. If your shares are held in Street name (by your broker), you must contact your broker to update your address.

MindMed’s Nasdaq listing provides its shareholders with sufficient liquidity, as Nasdaq accounts for approximately 95% of its trading volume when compared to the average daily trading volume of MindMed’s shares on the Cboe Canada exchange. The lower level of liquidity on Cboe Canada means there are reduced trading opportunities for shareholders. Accordingly, the Company wishes to move to having Nasdaq as its sole listing.

The listing of the Company on the Cboe Canada requires the Company to incur additional corporate and administrative costs, including listing fees. The Company is seeking to minimize its expenditure and would cease incurring such additional costs if it were to delist from the Cboe Canada.

The delisting from the Cboe Canada and retention of a primary listing on Nasdaq is expected to fully leverage the Company’s increased institutional investor base and other financing options in the United States which currently has the largest and most active biotechnology capital markets ecosystem.

All of the Company's directors and employees reside outside of Canada, reflecting the Company's focus as a US-based biotechnology company.

Based on available information, the majority of the Company’s largest shareholders are located in the United States. This reflects the shift in the Company's shareholding base toward  U.S. institutional investors.

The main consequence of the delisting for shareholders is that, from the time the delisting takes effect on April 10, 2024 (Delisting Date), MindMed shares will no longer be quoted or traded on the Cboe Canada exchange under the ticker MMED.

Following delisting from Cboe Canada, MindMed’s shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and online brokers, have the ability to buy and sell securities listed on Nasdaq, MindMed’s Nasdaq listing will continue to provide shareholders with the same accessibility to trade the Company's common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade MindMed’s common shares on Nasdaq.

We understand that most brokers in Canada, including most discount brokers, have the ability to buy and sell securities listed on Nasdaq. If your broker is unable to trade on Nasdaq, then in order to trade your MindMed common shares you will need to open an account at a broker that is able to trade on Nasdaq.

No. MindMed’s common shares continue to be listed and traded on Nasdaq under the symbol: MNMD.

Yes. The delisting will not impact the number of shares that you own.

Your shares will trade on Nasdaq in US dollars, and if your account trades in a Canadian trading account, the value of your shares will be converted into Canadian dollars based on the practices of your broker.